# Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina

> **NCT03059251** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 2 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **BIOLOGICAL:** Obinutuzumab

## Key facts

- **NCT ID:** NCT03059251
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-31
- **Primary completion:** 2019-03-30
- **Final completion:** 2019-03-30
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2020-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03059251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03059251, "Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT03059251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*